These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 23053257

  • 1. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.
    JAMA; 2012 Mar 28; 307(12):1265-72. PubMed ID: 22453568
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ, Guan GX, Lu HS, Yang YH, Kang DY, Huang HG.
    J Surg Oncol; 2011 Dec 28; 104(7):760-4. PubMed ID: 21713778
    [Abstract] [Full Text] [Related]

  • 4. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    Acta Oncol; 2012 Apr 28; 51(4):528-36. PubMed ID: 22150077
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
    Izquierdo ME, Bonastre MT.
    Anticancer Drugs; 2012 Jun 28; 23 Suppl():S7-9. PubMed ID: 22739668
    [Abstract] [Full Text] [Related]

  • 8. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL, del Muro XG.
    Anticancer Drugs; 2012 Jun 28; 23 Suppl():S3-6. PubMed ID: 22739667
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z, Gao J, Gong J, Li J, Li Y, Wang X, Li Y, Shen L, Li J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov 25; 19(11):1286-1289. PubMed ID: 27928801
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF.
    Ann Surg Oncol; 2007 Mar 25; 14(3):1123-8. PubMed ID: 17195905
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.
    J Med Econ; 2013 Sep 25; 16(9):1106-19. PubMed ID: 23808902
    [Abstract] [Full Text] [Related]

  • 14. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul 25; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 15. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W.
    Med Sci Monit; 2007 Nov 25; 13(11):CR515-522. PubMed ID: 17968300
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.
    Digestion; 2013 Nov 25; 87(1):47-52. PubMed ID: 23343969
    [Abstract] [Full Text] [Related]

  • 17. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y, Hou YY, Tan YS, Lu SH, Hou J, Liu JL, Qin J, Shen KT, Sun YH.
    Zhonghua Zhong Liu Za Zhi; 2009 Aug 25; 31(8):597-601. PubMed ID: 20021947
    [Abstract] [Full Text] [Related]

  • 18. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK.
    J Manag Care Pharm; 2010 Sep 25; 16(7):482-91. PubMed ID: 20726677
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH, Wang PZ, Shao YF, Wu XT, Gu J, Li R, Wan DS, Ding KF, Shi YQ, Yu JR, Lu HS, Zou XM, Bi JW, Sun YH, Lu YF, Chen DD, Zhang XH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep 25; 9(5):383-7. PubMed ID: 17043955
    [Abstract] [Full Text] [Related]

  • 20. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
    Gronchi A.
    Eur J Cancer; 2013 Mar 25; 49(4):884-92. PubMed ID: 23206668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.